[Federal Register: December 7, 2006 (Volume 71, Number 235)]
[Notices]
[Page 70987]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr07de06-81]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated July 26, 2006, and published in the Federal
Register on August 2, 2006, (71 FR 43814), Orasure Technologies, Inc.,
Lehigh University, Seeley G. Mudd-Building 6, Bethlehem, Pennsylvania
18015, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (LSD) (7315).... I
4-Methoxyamphetamine (7411)................ I
Normorphine (9313)......................... I
Tetrahydrocannabinols (THC) (7370)......... I
Alphamethadol (9605)....................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Cocaine (9041)............................. II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Oxycodone (9143)........................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Oxymorphone (9652)......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk to manufacture controlled substance derivatives. These
derivatives will be used in diagnostic products created specifically
for internal use only.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Orasure Technologies, Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Orasure Technologies, Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-20744 Filed 12-6-06; 8:45 am]
BILLING CODE 4410-09-P